inotuzumab ozogamicin   Click here for help

GtoPdb Ligand ID: 8266

Synonyms: Besponsa® | CMC-544
Approved drug Immunopharmacology Ligand
inotuzumab ozogamicin is an approved drug (EMA & FDA (2017))
Compound class: Antibody
Comment: Inotuzumab ozogamicin is an antibody-drug conjugate (ADC) that targets delivery of the highly cytotoxic ozogamicin (a derivative of calicheamicin γ1) to CD22 (SIGLEC-2) +ve myeloid cells [1]. The calicheamicin derivative is N-acetyl gamma calicheamicin dimethylhydrazide as reported by DiJoseph et al (2004) [1].
Click here for help
1. DiJoseph JF, Armellino DC, Boghaert ER, Khandke K, Dougher MM, Sridharan L, Kunz A, Hamann PR, Gorovits B, Udata C et al.. (2004)
Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies.
Blood, 103 (5): 1807-14. [PMID:14615373]
2. Kantarjian HM, DeAngelo DJ, Stelljes M, Martinelli G, Liedtke M, Stock W, Gökbuget N, O'Brien S, Wang K, Wang T et al.. (2016)
Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.
N Engl J Med, 375 (8): 740-53. [PMID:27292104]